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Background: Illicit drug users have a high prevalence of HCV and represent the majority of newly infected persons
in the U.S. Despite the availability of effective HCV treatment, few drug users have been evaluated or treated for
HCV. Racial and ethnic minorities have a higher incidence and prevalence of HCV and higher HCV-related mortality.
Factors contributing to poor engagement in care are incompletely understood.
Methods: Fourteen mixed-gender focus groups of either African American or Latino/a drug users (N = 95)
discussed barriers to HCV testing and treatment. Themes were identified through content analysis of focus group
discussions.
Results: Many drug users were tested for HCV in settings where they were receiving care. Outside of these settings,
most were unaware of voluntary test sites. After testing HCV positive, drug users reported not receiving clear
messages regarding the meaning of a positive HCV test, the impact of HCV infection, or appropriate next steps
including HCV clinical evaluations. Many drug users perceived treatment as unimportant because they lacked
symptoms, healthcare providers minimized the severity of the diagnosis, or providers did not recommend
treatment. Mistrust of the motivations of healthcare providers was cited as a barrier to pursuing treatment. Social
networks or social interactions were a source of HCV-related information and were influential in shaping drug users
perceptions of treatment and its utility.
Conclusion: Drug users perceived a paucity of settings for self-initiated HCV testing and poor provider-patient
communication at test sites and during medical encounters. Notably, drug users reported having an unclear
understanding about the meaning of a positive HCV test, the health implications of HCV infection, the importance
of clinical evaluations and monitoring, and of treatment options for HCV. Efforts to improve the delivery of clinical
messages about HCV infection for drug users at test settings and clinical encounters are needed.
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Hepatitis C virus (HCV) is a blood-borne infection most
efficiently spread via direct parenteral exposure through
non-sterile injection practices [1-4]. The World Health
Organization estimates a global prevalence of HCV of
2%, or 123 million people [5] most of whom are chronic-
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reproduction in any medium, provided the orborne infection in the United States and worldwide, and
accounts for roughly one quarter of all cases of cirrhosis
and hepatocelluar carcinoma [6,7]. HCV is hyperendemic
among people who inject drugs, representing the largest
group of infected persons both worldwide, and in each
country where HCV prevalence and risk factor data are
available [8-10]. The estimated global prevalence of HCV
among IDUs ranges from 9.8% to upwards of 97%, with
most estimates falling between 50-90% in regions with
long-standing endemic injection drug use [1,4]. The
incidence of HCV among IDUs ranges regionally from
10 to 40 per 100 person-years at risk [1,11]. HCV isLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with men, often in association with non-injection illicit
drug use [12,13].
HCV causes chronic infection with persistent viremia
in the majority of those infected (~85%) [14]. As a result,
chronically infected persons constitute a significant res-
ervoir of HCV creating an environmental transmission
dynamic that increases the probability that a non-sterile
injection episode will be with a chronically HCV-infected
person [1,11]. Important sequelae of chronic HCV are liver
fibrosis leading to cirrhosis; liver failure; and hepatocellular
carcinoma [15]. Studies suggest that over the course of
two decades, 20-30% of chronically HCV infected persons
will develop cirrhosis, with an estimated 10,000-20,000
early deaths [14]. In the United States, the disease burden
is predicted to increase up to 3-fold over the course of the
next 10–20 years [15]. The efficacy of HCV treatment has
improved in recent years with the introduction of direct-
acting antivirals (e.g., telaprevir and boceprevir) and the
prospect of interferon-free regimens [16,17]. For many,
fear of adverse effects of HCV treatment is a barrier to
treatment initiation and may contribute to treatment non-
adherence and treatment discontinuation [18-21]. While
HCV treatment has the potential to cure the virus in 40-
80% of patients, current treatment is arduous, lengthy, ex-
pensive and remains inaccessible for many drug users [15].
The majority of drug users remain out of HCV care,
and few are engaged in treatment [18,21-24]. Many
HCV positive drug users have not been evaluated for
HCV treatment; are less likely to see an HCV specialist
or to get an HCV RNA polymerase chain reaction (PCR)
test to document chronic active infection; and are less
likely to be receiving antiviral treatment for HCV com-
pared to non-injection drug users [18,21,25]. Active drug
use has been shown to not have a direct, negative effect
on treatment efficacy [8,9,26-28]. It is estimated that less
than half of drug users with chronic HCV have been of-
fered treatment ever [17].
Racial/ethnic minorities are less likely to receive anti-
retroviral therapy for HIV [29,30]. Some prior qualitative
studies have highlighted drug users’ misconceptions and
lack of understanding about HCV, racial and ethnic mi-
norities have a higher incidence and prevalence of HCV
and higher HCV-related mortality [18,31-35]. Drug users
often have limited access to health care and may experi-
ence or perceive stigmatization that poses a barrier to care
[23,35]. Additionally, some drug users report that drug
use-related stigma is a barrier to HCV testing. Rates of
HCV are higher in racial/ethnic minority drug users [36].
Further data to inform the delivery of clinical messages
about HCV infection for drug users at test settings and
clinical encounters are needed.
This study sought to explore racial/ethnic minority drug
users’ attitudes, perceptions, and experiences regardingHCV and HIV testing, referrals and treatment, through
focus groups with drug users in San Francisco and New




Fourteen focus groups with a total of 95 participants
were conducted in New York City (6 focus groups) and
San Francisco (8 focus groups) in three recruitment set-
tings: HIV primary care clinics, methadone maintenance
treatment (MMT) programs and syringe exchange pro-
grams (SEP). During the course of the study, the HIV
clinics both conducted HCV testing and the site in NYC
provided on-site HCV treatment; the MMT programs
offered anti-HCV testing, but neither viral load testing
nor HCV treatment; and the SEPs did routinely offer
HCV testing but offered no on-site HCV care. Eligibility
criteria required that participants be 18 years of age or
older; self-identify as African-American or Latino/a; and
be receiving services at one of the recruitment sites. Par-
ticipants were excluded from the study if they had severe
cognitive impairment, suicidal ideation, or active psychosis.
The study included persons who have used illicit drugs in
the past 12 months by either injection or non-injection
routes; non-injection illicit drug users were included be-
cause of data demonstrating rates of HIV in non-
injectors comparable to injectors in many cities [3] and
because of concerns of HCV transmission via drug
using paraphernalia and networks [1]. The terms ‘drug
users’ and ‘injection drug users’ (IDUs) are used
throughout the text where appropriate. This manuscript
reports on findings with respect to HCV testing and
treatment. This study was approved by the Institutional
Review Boards of Beth Israel Medical Center and the
University of California, San Francisco.
Participants were recruited through staff referrals at
each of the recruitment sites regardless of HCV status or
prior testing experience. Participants were told that the
goals of the focus group were to explore participants’ ex-
periences with HIV and HCV testing and care. The
number of participants in each group ranged from 3 to
12. All focus groups were of homogenous race/ethnicity,
consisting of either Latino/a or African American partic-
ipants. The rationale for race/ethnicity specific focus
groups was to identify possible race/ethnicity specific is-
sues with regard to HIV and HCV testing and care. All
focus groups were conducted in English. Participants
provided informed consent and were reimbursed $25 for
their participation in the study.
Focus groups were conducted by PhD-level qualitative
researchers, bi-lingual in English and Spanish; each
group lasted roughly 90 minutes. The focus groups used
a semi-structured qualitative interview guide designed to
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related to HIV and HCV including: self-perceived risk;
general knowledge of the viruses; prior experiences and
current feeling about seeking testing; prior pre- and
post-test experiences; and prior experiences accessing or
remaining engaged in treatment. Further, the interview
guide also included open ended queries about individ-
ual’s drug use histories, knowledge of their own HIV/
HCV status, and perceptions about race/ethnicity in
relation to testing and care (the focus group guide is
available from the corresponding author). Participants
recruited for these focus groups were not tested sero-
logically: those recruited from HIV clinics were known
to be HIV infected; for others HIV status was by self-
report; and for all, HCV status was self-reported. 39%
reported HIV infection (21% of the total reported HCV/
HIV co-infection), 36% reported HCV mono-infection,
and the rest reported unknown status. All focus groups
were audio taped and transcribed verbatim.Qualitative data analysis
Transcripts were coded and analyzed using Atlas.ti V.5
software. At least two researchers individually reviewed
and independently coded all transcripts and discussed
ambiguities. Grounded theory [37] analytic techniques
were used to seek patterns in the data and to develop
emergent hypotheses about them. Analysis began by
coding verbatim references containing any of the fol-
lowing codes: HCV/HIV testing, access to HCV/HIV
care, HCV/HIV treatment, racial/ethnic minority sta-
tus, co-infection and drug user status. Two emerging
codes were added during the analysis: “medical mis-
trust” and “stigma”.Results
Fourteen focus groups were conducted, 6 in NYC and 8
in San Francisco. The 6 in NYC included one with
Latino/a participants and one with African American
participants at each of the three recruitment settings
(MMT, SEP, and HIV clinic) with a total of 51 partici-
pants. The 8 in San Francisco included 2 with African
American and 1 with Latino in MMT; 2 Latino and 1
African American at HIV primary care; and 1 African
American and 1 Latino at SEP, with a total of 44 partici-
pants. The total sample of 95 participants was 41% fe-
male (n=39); average age was 45 years (minimum 32,
maximum 58). The analysis discusses results related to
access to HCV testing, post-test counseling and medical
care, experience with HCV treatment and perceptions of
HCV treatment. No differences between testing experi-
ences emerged by gender or between focus groups in
NYC and San Francisco hence, results are reported in
aggregate.HCV testing
In focus groups, nearly all participants reported having
been tested for HCV. Participants generally described an
HCV testing experience that consisted of testing at the
structured settings in which they were receiving care,
with tests commonly having been initiated by health care
providers with knowledge of participants’ risk factors for
HCV. The primary settings in which participants were
tested for HCV were MMTs and SEPs. Common to
those who were or had been in MMT was a perception
that routine HCV testing was a mandatory component
of the intake exam and annual physicals for all MMT
patients: “You’re on methadone, it’s a requirement any-
way, to get tested for [HCV]” (African American male);
no one reported objecting to being tested for HCV in
this way. This perceived routinization of HCV testing was
also reported by participants who underwent testing at
health care sites where tests were usually initiated by
health care providers and where the reason for the ap-
pointment was to receive care for other illnesses: “I did
[HCV] testing when getting [treatment for] pneumonia”
(Latino). Such testing often took place without partici-
pants being aware that they were tested for HCV: “I found
out afterwards [that I was tested for HCV]. [The doctor]
tested it on his own”. (Latino).
While testing for HCV was common among focus
group participants, most reported being unaware of vol-
untary testing sites. Most participants were eager to have
access to voluntary HCV testing. Focus group partici-
pants did not report seeking self-initiated HCV testing
outside of MMT, SEP, jail and HIV primary care settings:
“Most people just don’t know where to do it [HCV test],
unless you go to the exchange and they happen to be
doing it there” (African American male); “You have to
find a way to get it [HCV test]; It ain’t like-come and
get a hep C test. It’s like a best-kept secret” (African
American male).
Underscoring the reality that HCV is a widely asymp-
tomatic disease, only one participant reported seeking
medical attention because they experienced symptoms
associated with an HCV infection: “I had yellow jaun-
dice. Like my urine was orange, real dark orange […] At
least the doctor told me [I was HCV positive]” (African
American female).
These patterns of HCV testing experiences contrasted
with participant reports regarding HIV testing, which
were characterized by frequent and self-initiated testing
with access to ubiquitous testing sites: “HIV testing is
much more accessible to me, more accessible than hepa-
titis C” (African American female). Participants had a
high degree of awareness of available HIV testing sites:
“The fact that they’re so accessible, I feel like if any day I
feel like getting up and going to get [an HIV] test, I can
get it the very same day” (Latina). Many participants
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Experiences with HCV post-test counseling and referrals
Despite their individual histories of drug use, many par-
ticipants were surprised when they were first diagnosed
with HCV: “My doctor took blood, and he tested it and
he told me I had hepatitis C, and that was my first time
knowing about it […] I was an injector”. (African
American male)
Many participants found to be HCV positive reported
receiving their results but coming away from post-test
counseling without a clear understanding of the signifi-
cance of the diagnosis or what next steps to take: “I
found out I was hep C positive. [The doctor] told me
the basics but they never really told me what the next
step was”. (Latino) Participants reported confusion and
uncertainty given their new situation: They had been
given a diagnosis of HCV, but did not come away with a
clear understanding of the health implications or what
to do next:
You’re hep C positive, but now what? they should
have a place to send them or I should have somebody
some place at my facility to at least counsel them.
Nobody has even spoken to them. (African American
male)
They won’t refer you to nobody, see they just told me
and just left me hanging. Just left me there. (African
American female)
They didn’t give me nothing to go on. I had nothing
to take home with me and sit down and study and go
over myself… they don’t have nothing for the poor
person that has contracted hep C. Nobody where I
got tested at gave me any literature. (African
American female)
Accompanying the feelings of uncertainty regarding an
HCV diagnosis, many participants described feeling fa-
talistic with a generalized nihilism about managing their
infection: “I don’t know what to do. Except just walk
around dying from it” (African American male).
Participants specifically described a lack of explanation
and clarity regarding the treatment options for HCV and
they were eager for more information and a better un-
derstanding of HCV treatment: “When I first found out
I had hepatitis C, they didn't suggest any kind of treat-
ment. It was only two or three years later that they made
me an appointment for the hospital to go” (Latina).
As part of this uncertainty about treatment, many
people came away with an implicit message that there
was not much else that could or needed to be done totreat HCV or to prevent liver damage. As one participant
explained: “Everybody says there’s really nothing too much
to do when you got that [HCV]. They just say, yeah, I got
it, as far as hep C, and they [health care providers] just let
you know” (African American male). Participants also
reported disengaging from care once they found out they
weren’t eligible for treatment or that treatment wasn’t ne-
cessary for them at that point in time.
So he told me that if you want, take a biopsy if you
want it, that was my option. So I didn't do it. He said,
but your liver seems like it's okay. The numbers are in a
good-good place […] So I dropped it at that. (Latino)
Some participants, despite having been told they were
HCV positive, did not believe they were infected because
their providers did not offer them treatment: “I don't be-
lieve them [the doctors] for the simple fact they didn't
give me, they didn't give me no medicine for it [HCV]”;
“I’m sure he will if I have hep C, he will tell me take this
and this medication. He will order it. So I do not believe
I have hep C” (African American male).Experiences with HCV treatment evaluations
Among participants who reported receiving HCV treat-
ment evaluations, many said that they were told by
health care providers that due to the healthy state of
their liver and the results of various tests to assess their
infection, treatment was not recommended at that time.
Some understood that treatment was not offered be-
cause there was no evidence of liver damage. Many par-
ticipants reported not initiating HCV treatment because
their providers either did not discuss or recommend it:
“My doctor told the same thing that everything was fine,
not to worry about it [HCV] […] that the numbers were
low and that I didn't need no medication or anything”
(Latina); “[My doctor told me] I didn’t need a treatment
because it wasn’t bad […] My liver wasn’t inflamed, and
I was doing okay […] there was no need for medication
until years down the line” (African American male).
While some people came away from HCV evaluations
understanding that treatment was indicated if there was
substantial liver damage and may not be otherwise neces-
sary, many participants did not have a thorough under-
standing and felt as if they were left in limbo with a
positive diagnosis without clear options. Participants who
were evaluated but not offered treatment commonly
reported being counseled about reducing drug and alcohol
use and avoiding excess acetaminophen, “[the doctor] told
me that […] just don't drink any alcohol and don't abuse
them, stuff that's going to irritate the liver”. (Latino)
There were few participants who reported being en-
couraged to have regular medical follow-up to monitor
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treatment.
I went according to my doctor. He said that my viral
load was okay, so I took—I took it like that, okay, so
then I'm fine. Every month, you go see that doctor
[…] on a monthly basis and stay—stay with blood
work. (Latino)
Few participants in the focus groups had initiated
HCV treatment; however, of those who reported initiat-
ing treatment, they all discontinued treatment due to ad-
verse drug reactions.
I decided to treat it [HCV] […] I only did it for like
four months because I ended up getting some side
effects […] The medication was doing things that I
dislike […] I told [my doctor] that I am not taking it
anymore. (Latino)
For the participants who reported being offered treat-
ment, many reported that the low odds of eradicating
the virus deterred them from initiating treatment. Add-
itionally, one participant reported that their provider did
not recommend treatment saying the patient was
infected with an HCV genotype that was poorly respon-
sive to treatment.
Perceptions of HCV treatment
Knowledge and perceptions about HCV treatment often
came from peers, and the messages communicated were
often discouraging of treatment. While a few patients
had previously initiated HCV treatment, most had no
direct treatment experience. Participants reported that
these communications with peers raised anxiety about
the potential adverse side effects of the medication: “I
didn’t even know what the process was […] I found out
through someone who had hep C, and her experience
through it” (Latino).
Participants with HCV were uniformly eager to learn
more about HCV treatment and how to stay healthy.
Among participants who reported discussing treatment
with a health care provider, or who were offered treat-
ment, the majority felt dissuaded from pursuing it.
While some participants reported an interest in treat-
ment, the consideration of “everything that goes with it”,
including not wanting to endure the serious side effects
of treatment, was the primary reason that participants
chose not to initiate treatment. Among HCV-positive in-
dividuals in particular, there was a common perception
that HCV treatment was worse than the disease due to
the difficulty in coping with the length of treatment and
medication side effects: “[There are] bad reactions that a
lot of people have with medication. Some people getsuicidal, depression […] They’d get lonely, you know, de-
pressed, big, big stay of depression” (Latino).
Many participants while willing and even eager to con-
sider HCV treatment, many articulated that these fears of
lengthy treatment and severe adverse effects- discouraged
them from pursuing treatment. Additionally, participants
reported believing that treatment might be harmful to
their liver, might cause HCV infection or other harmful
physical adverse effects, and be inefficacious: “Interferon
I’ve heard is the treatment for it but I’ve heard that the
treatment is worse than the disease and it’s not effective”.
(Latino) Such concerns lead many infected but asymp-
tomatic participants to not seek treatment; as one partici-
pant explained it: “if it ain’t broke, don’t fix it” (African
American male). This attitude was common; participants
reported believing that it was more advantageous to their
health to not seek treatment rather than pursue treatment
and risk making their health worse: “my liver function is
still good, so I’m not going [to] take something that’s go-
ing [to] make me worse” (Latino).
In contrast, across focus groups, participants’ overall
knowledge about HIV and treatment options was exten-
sive, regardless of their HIV status. Participants under-
stood opportunistic infections; various tests indicating
HIV/AIDS status; treatment outcomes; and the necessity
of treatment to control the infection “If you’re told you
got HIV […] it’s not like before, like it’s more manageable,
you can live longer […] there’s so many drugs that can
help with it”. (Latina)
In addition to their individual concerns about HCV,
participants also regarded HCV as a virus infecting and
affecting drug users rather than non-drug users. They
concluded that the paucity of HCV services and the
lack of effective treatment options were the result of
stigma and marginalization of IDUs. In addition, par-
ticipants described their belief that socioeconomic
factors and insurance availability influenced their doc-
tors’ decision making regarding the provision of HCV
treatment.
If you have private insurance […] They’ll give you all
the treatment and health that you want…but because
they know that Medicaid is not going to pay them
their money on time- they’re going to get paid […]
they’re not ready and willing to offer this treatment
[to those with Medicaid]. (Latino)
I think a lot has to do with – people who – the
powers that be don’t use drugs like we use drugs. It
[HCV] don’t affect them. (African American male)
One participant explained that she felt mistreated
by her doctor: “They kick you to the side”. (African
American female)
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manifested in other ways. Some participants reported
believing that their providers were diagnosing, and even
misdiagnosing HCV to receive insurance payments for
their visits.
Implications of drug use
One of the barriers participants reported complicating
engagement in HCV care was active drug use. Partici-
pants reported that when they were using actively they
were less likely to get tested for HCV, “Personally, I
wouldn’t put down no syringe […] to go get tested [for
HCV]” (Latino); “It took me so long [to get tested]
because I was getting high”. (Latino) One participant
explained that her commencing HCV care occurred “fast
as my addiction would let me go”. (African American fe-
male) Active drug use not only emerged as a barrier to
participants’ willingness to engage in HCV testing, but
also as a barrier to clinical follow-up after receiving a
HCV diagnosis. Participants reported that the consuming
nature of drug use precluded any motivation to seek care.
One participant attributed his active heroin use to his in-
ability to schedule an appointment for an HCV evaluation
from a referral he received after being tested for HCV:
Yes, [the doctor] told me … numerous times. I just
didn’t do it. Either I forgot about it or was just too
lazy to get up off my ass and go do it. I got a thing
about keeping appointments […] it’s the dope’s fault.
(African American male)
Discussion
It is estimated that about 60-90% of drug users are
infected with HCV [14,38,39]. Focus groups with drug
users in MMT, SEP and HIV Primary Care reveal that
prior to a diagnosis of HCV, most participants had a
poor understanding of HCV and its significance. After
being diagnosed, many participants reported not receiv-
ing a clear message regarding what the infection meant;
their HCV status; and next steps, including follow-up
evaluations and the availability, role and efficacy of treat-
ment options. Participants also reported some mistrust
of health care providers, recognizing that active drug use
is a barrier and commonly reported not receiving refer-
ral for HCV clinical evaluation after receiving a positive
test result.
Many drug users come into contact with drug treat-
ment programs and/or drug related services such as nee-
dle exchange. These programs serve as important points
of access for health services. In focus groups discussions,
participants explained that programs for drug use served
as primary settings in which they received HCV testing.
SEPs and MMTs along with other clinical settings were
structured settings in which participants reportedreceiving HCV testing. Our findings underscore the im-
portance and utility of providing HCV testing in drug
treatment programs or programs aimed at serving drug
users. In our sample the majority of drug users had
reported receiving at least one HCV test in the past; this
has not been the case in all previous studies [35,39]. This
may relate to participants’ having been recruited in clinical
or harm reduction settings.
In contrast to ready access to voluntary HIV testing,
participants in our study reported limited access to vol-
untary HCV testing. Participants in numerous studies
reported feeling most comfortable accessing HCV test-
ing and HCV-related services at sites where providers
had an understanding of addiction and were accustomed
to and respectful of drug users [15,40]. In our study, par-
ticipant comments also suggested that in the health care
systems they accessed, there were few settings available
for voluntary HCV setting (e.g., mobile HIV testing but
no HCV testing vans). In this way, and in the learned ex-
perience of our focus group participants, offering both
targeted and voluntary testing at sites where drug users
are already receiving services, in settings widely popu-
lated by drug users, could serve as effective points of
entry for drug users to initiate and maintain care for
their HCV infections.
Overall, participants reported a gap between testing
and receiving referrals to medical evaluations following a
positive HCV test result. Many publications document
low rates of referral after testing positive [27,34,35] but
it is usually assumed that this gap is due to patient non-
adherence; our data demonstrates drug users perceive
not having had received referrals. Participants reported
feeling abandoned by clinicians, a finding that is consist-
ent with other studies of HCV testing among drug users
[15,41]. It is important to note that the same barriers
that participants identified may also contribute to pro-
vider reluctance to initiative HCV treatment for drug
users, however, several studies have highlighted that with
appropriate attention to these issues, active drug users
can be successfully treated for HCV [9].
Most participants in our study were unclear about
how HCV infection should be evaluated and monitored,
and about treatment. Some participants also perceived
HCV treatment as something available to the wealthy
and not to marginalized groups or those on Medicaid.
Others were suspicious that HCV was diagnosed and
treatment offered more for profit than to improve the
health and well-being of patients. It is difficult to know
whether these perceptions were based on a lack of under-
standing of HCV infection and treatment (a knowledge
deficit) versus based primarily on emotional factors such
as medical mistrust. The former would be amendable to
educational efforts while the latter would require being
addressed by other intervention strategies.
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heavily on peers for HCV treatment knowledge suggests
that support from peers may be a valuable way to engage
drug users in HCV care. This finding is consistent with
qualitative studies that have been published on this topic
[15,40]. This peer-gained knowledge of HCV and its treat-
ment is maintained through peer relationships. These
forums serve a critical role in disseminating information
about HCV to those either untreated, out of care or who
have not received adequate information from their pro-
viders [8].
The findings presented in this paper should be
interpreted with some caution as reported experiences
may not be generalizable to all drug users in all settings. It
is possible that the focus group framing or even the nature
of discussing these issues in a group setting may have led
to reporting bias. There may also be other factors that did
not emerge in the discussions. Due to the design of the
study, for those participants recruited at sites other than
HIV clinics, HIV status was my self-report and for all par-
ticipants HCV status was self-reported. Further, we could
not confirm self-reports of prior testing and it is therefore
important to note that what patients reported were their
perceptions and memories. Also, it is impossible to dis-
cern the extent to which HCV treatment was medically
necessary for the HCV-positive focus group participants.
The data collected through focus groups are qualitative
and further quantitative survey data about the proportion
of DUs having positive, neutral, or negative experiences
would be valuable. Further, these focus groups were
conducted during 2008–2009 and issues of awareness and
access may have changed; however, the availability of im-
proved therapies only increases the need to have clear un-
derstandings of potential barriers. Finally, due to funding
limitations, 1) focus groups were not conducted with
white drug users, which would have been useful for com-
parison; and 2) only English-speaking drug users were eli-
gible for this study, and therefore our findings may not
reflect those of non-English speaking drug users.
HCV remains a critical public health challenge among
drug users, and the numbers of deaths due to HCV have
surpassed those due to HIV/AIDS [42]. A recent meta-
analysis has demonstrated that a sustained virologic re-
sponse after treatment is associated with a reduced
incidence of hepatocellular carcinoma underscoring the
importance of engaging HCV infected patients in treat-
ment [43]. HCV is a major cause of preventable morbid-
ity and mortality among IDUs; scaled-up efforts to
prevent HCV are imperative. Efforts to increase or
establish HCV surveillance as well as the development
of comprehensive and effective strategies to reduce
transmission among IDUs are urgently needed. Public
health approaches to HCV may benefit from expanding
access to and awareness of voluntary HCV testing sitesand treatment services. Standardized post-test counsel-
ing messages and active referral are critical in efforts to
promote stronger linkages between HCV testing and care.
Concrete, active referral linkages may also be needed [44].
Additionally, as with the Seek, Test, and Treat strategy be-
ing employed to reduce population HIV rates, programs
targeted at increasing rates of HCV treatment among drug
users might be an important strategy to reduce the num-
ber of HCV-positive persons, thus reducing both overall
risk to individual drug users and reducing HCV preva-
lence at the population level.
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